^
    1d
    Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies (clinicaltrials.gov)
    P2/3, N=90, Not yet recruiting, Nanfang Hospital, Southern Medical University
    New P2/3 trial
    |
    Reblozyl (luspatercept-aamt)
    2d
    A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS) (clinicaltrials.gov)
    P2, N=10, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=40 --> 10
    Enrollment closed • Enrollment change
    |
    Reblozyl (luspatercept-aamt)
    2d
    HARMONIZE: Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023) (clinicaltrials.gov)
    P2, N=130, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Winrevair (sotatercept-csrk)
    7d
    ELRISE MF: A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib (clinicaltrials.gov)
    P3, N=324, Not yet recruiting, Takeda
    New P3 trial
    |
    Jakafi (ruxolitinib) • elritercept (KER-050)
    8d
    A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, Bristol-Myers Squibb | Initiation date: Feb 2026 --> Jun 2026
    Trial initiation date • Real-world evidence
    |
    Reblozyl (luspatercept-aamt)
    12d
    Pirfenidone Inhibits Inflammatory Mediators in Human Cornea In Vitro. (PubMed, J Ocul Pharmacol Ther)
    PFD inhibits corneal inflammation in vitro by reducing pro-inflammatory cytokines and oxidative stress. Comprehensive preclinical animal testing is warranted to define the potential of PFD to treat corneal symptoms in vivo in traumatic eyes.
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • GPX4 (Glutathione Peroxidase 4) • IL1A (Interleukin 1, alpha) • IL1B (Interleukin 1, beta) • CAT (Catalase)
    14d
    A Trial of Y101D in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Advanced Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=71, Completed, Wuhan YZY Biopharma Co., Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    gemcitabine • albumin-bound paclitaxel
    14d
    Ethanol promotes oxaliplatin resistance in colorectal cancer by activating the TGF‑β/Smad/P21 signaling axis (PubMed, Nan Fang Yi Ke Da Xue Xue Bao)
    Ethanol accumulation activates the TGF-β/Smad/P21 axis to induce cell cycle arrest and promote oxaliplatin resistance in CRC cells, which can be partially reversed by pirfenidone inhibition.
    Journal
    |
    RB1 (RB Transcriptional Corepressor 1) • TGFB1 (Transforming Growth Factor Beta 1) • ADH1C (Alcohol Dehydrogenase 1C (Class I), Gamma Polypeptide) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • ADH1B (Alcohol Dehydrogenase 1B (Class I), Beta Polypeptide) • SMAD2 (SMAD Family Member 2)
    |
    oxaliplatin
    14d
    A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing） (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Sinocelltech Ltd.
    New P2 trial
    |
    EGFR positive
    |
    docetaxel
    15d
    HARMONIZE: Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023) (clinicaltrials.gov)
    P2, N=130, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Mar 2029 --> Aug 2035 | Trial primary completion date: Mar 2029 --> Aug 2035
    Trial completion date • Trial primary completion date
    |
    Winrevair (sotatercept-csrk)
    19d
    A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037) (clinicaltrials.gov)
    P4, N=30, Not yet recruiting, Merck Sharp & Dohme LLC
    New P4 trial
    |
    Winrevair (sotatercept-csrk)
    23d
    Treatment Patterns and Outcomes in Patients With Lower-risk Myelodysplastic Syndromes Treated With Luspatercept in China (clinicaltrials.gov)
    P=N/A, N=88, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed | Trial completion date: Nov 2025 --> May 2026 | Trial primary completion date: Nov 2025 --> May 2026
    Trial completion • Trial completion date • Trial primary completion date • HEOR • Real-world evidence
    |
    Reblozyl (luspatercept-aamt)